ITC
New York · Founded 1969
About ITC
ITC was founded in 1969 by brothers Michael and Joel Mintz, answering the call of clinicians for a point-of-care coagulation test device for monitoring Activated Clotting Time (ACT). Since 1969, ITC has played an important role in the delivery of cardiovascular care by providing critical data when and where it is needed most. Through the years, ITC has expanded its product portfolio through both internal product development and through acquisition of complimentary point-of-care products. Today, ITC platforms include Hemochron® RXDX® dosing technology, Hemochron microcuvette technology, ProTime® microcoagulation testing for PT/INR monitoring, IRMA TruPoint® blood analysis system, Avoximeter® CO-oximetry and oximetry testing and Tenderfoot® incision devices for newborns.
Company Facts
- Founded: 1969
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 501 – 1,000
- Estimated revenue: $1K – $10K
- Total funding: $72.5M
- Last round: Series Unknown (Nov 2010)
- Website: itcmed.com
- Phone: 8102204076
Social Profiles
Canonical: https://fsome.com/organization/itc-8445553 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.